Neurofibromatosis Type 1 Global Market Report 2025

Neurofibromatosis Type 1 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurofibromatosis type 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for neurofibromatosis type 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurofibromatosis type 1 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Treatment: Medication; Surgery; Radiation Therapy; Other Treatments

2) By Disease Type: Plexiform Neurofibromas; Cutaneous Neurofibromas; Optic Gliomas; Other Diseases

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

4) By End Users: Hospitals; Speciality Clinics; Ambulatory Surgical Centers; Other End Users

Subsegments:

1) By Medication: Targeted Therapy; Pain Management Medications; Anticonvulsants

2) By Surgery: Tumor Removal Surgery; Nerve Decompression Surgery

3) By Radiation Therapy: Stereotactic Radiosurgery; External Beam Radiation Therapy

4) By Other Treatments: Physical Therapy; Genetic Counseling; Psychological Support And Counseling

Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; Novartis AG; AstraZeneca Plc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Executive Summary
2. Neurofibromatosis Type 1 Market Characteristics
3. Neurofibromatosis Type 1 Market Trends And Strategies
4. Neurofibromatosis Type 1 Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Neurofibromatosis Type 1 Growth Analysis And Strategic Analysis Framework
5.1. Global Neurofibromatosis Type 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurofibromatosis Type 1 Market Growth Rate Analysis
5.4. Global Neurofibromatosis Type 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurofibromatosis Type 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurofibromatosis Type 1 Total Addressable Market (TAM)
6. Neurofibromatosis Type 1 Market Segmentation
6.1. Global Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medication
Surgery
Radiation Therapy
Other Treatments
6.2. Global Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plexiform Neurofibromas
Cutaneous Neurofibromas
Optic Gliomas
Other Diseases
6.3. Global Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Neurofibromatosis Type 1 Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Speciality Clinics
Ambulatory Surgical Centers
Other End Users
6.5. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Pain Management Medications
Anticonvulsants
6.6. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Removal Surgery
Nerve Decompression Surgery
6.7. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stereotactic Radiosurgery
External Beam Radiation Therapy
6.8. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Physical Therapy
Genetic Counseling
Psychological Support And Counseling
7. Neurofibromatosis Type 1 Market Regional And Country Analysis
7.1. Global Neurofibromatosis Type 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurofibromatosis Type 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Neurofibromatosis Type 1 Market
8.1. Asia-Pacific Neurofibromatosis Type 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Neurofibromatosis Type 1 Market
9.1. China Neurofibromatosis Type 1 Market Overview
9.2. China Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Neurofibromatosis Type 1 Market
10.1. India Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Neurofibromatosis Type 1 Market
11.1. Japan Neurofibromatosis Type 1 Market Overview
11.2. Japan Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Neurofibromatosis Type 1 Market
12.1. Australia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Neurofibromatosis Type 1 Market
13.1. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Neurofibromatosis Type 1 Market
14.1. South Korea Neurofibromatosis Type 1 Market Overview
14.2. South Korea Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Neurofibromatosis Type 1 Market
15.1. Western Europe Neurofibromatosis Type 1 Market Overview
15.2. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Neurofibromatosis Type 1 Market
16.1. UK Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Neurofibromatosis Type 1 Market
17.1. Germany Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Neurofibromatosis Type 1 Market
18.1. France Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Neurofibromatosis Type 1 Market
19.1. Italy Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Neurofibromatosis Type 1 Market
20.1. Spain Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Neurofibromatosis Type 1 Market
21.1. Eastern Europe Neurofibromatosis Type 1 Market Overview
21.2. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Neurofibromatosis Type 1 Market
22.1. Russia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Neurofibromatosis Type 1 Market
23.1. North America Neurofibromatosis Type 1 Market Overview
23.2. North America Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Neurofibromatosis Type 1 Market
24.1. USA Neurofibromatosis Type 1 Market Overview
24.2. USA Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Neurofibromatosis Type 1 Market
25.1. Canada Neurofibromatosis Type 1 Market Overview
25.2. Canada Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Neurofibromatosis Type 1 Market
26.1. South America Neurofibromatosis Type 1 Market Overview
26.2. South America Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Neurofibromatosis Type 1 Market
27.1. Brazil Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Neurofibromatosis Type 1 Market
28.1. Middle East Neurofibromatosis Type 1 Market Overview
28.2. Middle East Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Neurofibromatosis Type 1 Market
29.1. Africa Neurofibromatosis Type 1 Market Overview
29.2. Africa Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Neurofibromatosis Type 1 Market Competitive Landscape And Company Profiles
30.1. Neurofibromatosis Type 1 Market Competitive Landscape
30.2. Neurofibromatosis Type 1 Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
31. Neurofibromatosis Type 1 Market Other Major And Innovative Companies
31.1. Takeda Pharmaceutical Company Limited
31.2. Boehringer Ingelheim International GmbH
31.3. Vertex Pharmaceuticals Incorporated
31.4. Shanghai Fosun Pharmaceutical (Group) Co. Ltd
31.5. BeiGene Ltd.
31.6. BioMarin Pharmaceutical Inc
31.7. Exelixis Inc.
31.8. Blueprint Medicines Corporation
31.9. SpringWorks Therapeutics Inc
31.10. Onclive LLC
31.11. Healx Limited
31.12. Infixion Bioscience Limited
31.13. NFlection Therapeutics Inc
31.14. Pasithea Therapeutics Corporation
31.15. Mulberry Biotherapeutics Inc.
32. Global Neurofibromatosis Type 1 Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Neurofibromatosis Type 1 Market
34. Recent Developments In The Neurofibromatosis Type 1 Market
35. Neurofibromatosis Type 1 Market High Potential Countries, Segments and Strategies
35.1 Neurofibromatosis Type 1 Market In 2029 - Countries Offering Most New Opportunities
35.2 Neurofibromatosis Type 1 Market In 2029 - Segments Offering Most New Opportunities
35.3 Neurofibromatosis Type 1 Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings